Clinical and Experimental Neuroimmunology 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Transverse myelitis following bivalent COVID ‐19 booster vaccine and quadrivalent seasonal influenza vaccine
(Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - January 25, 2023 Category: Neurology Authors: Teresa L. Xiao,
Alexandre Zaharia,
Anas S. Al ‐Smadi,
Caleb J. Murphy Tags: CLINICAL LETTER Source Type: research
The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert –Eaton myasthenic syndrome
AbstractThe revised Japanese clinical guidelines for myasthenia gravis (MG) and Lambert –Eaton myasthenic syndrome (LEMS) were published in 2022. The notable points in these guidelines (GLs) are as follows. 1) These are the first Japanese GLs to include a description of LEMS. 2) Diagnostic criteria of MG are revised to lessen the incidence of false-negative patients. 3) MG is divided into six clinical subtypes. 4) A high-dose oral steroid regimen with escalation and de-escalation schedule is not recommended by the GLs. 5) The GLs promote the early fast-acting treatment strategy initially proposed in the previous GLs. 6) ...
Source: Clinical and Experimental Neuroimmunology - January 10, 2023 Category: Neurology Authors: Hiroyuki Murai,
Kimiaki Utsugisawa,
Masakatsu Motomura,
Tomihiro Imai,
Akiyuki Uzawa,
Shigeaki Suzuki Tags: INVITED REVIEW Source Type: research
All differential diagnoses of cerebellar ataxia should be ruled out before SARS ‐CoV‐2 is blamed as the cause
(Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - December 9, 2022 Category: Neurology Authors: Josef Finsterer Tags: LETTER TO THE EDITOR Source Type: research
Epidemiological study of myasthenia gravis in Japan
AbstractMyasthenia gravis (MG) is an autoimmune-mediated neurological disorder. The relationship between MG and thymic abnormalities is well recognized, and thymectomy is one of the therapies for anti-acetylcholine receptor (AChR) antibody-positive MG. The major pathogenic factor is anti-AChR antibody followed by anti-muscle specific kinase (MuSK) antibody, and commercial kits are available to detect these antibodies. Several decades ago, the prognosis of MG was not favorable; therefore, the Ministry of Health and Welfare (predecessor of the Ministry of Health, Labour and Welfare) organized a Taskforce for intractable dise...
Source: Clinical and Experimental Neuroimmunology - November 24, 2022 Category: Neurology Authors: Hiroaki Yoshikawa Tags: INVITED REVIEW Source Type: research
Corrigendum
(Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - November 13, 2022 Category: Neurology Tags: CORRIGENDUM Source Type: research
Issue Information
(Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - November 13, 2022 Category: Neurology Tags: ISSUE INFORMATION Source Type: research
Autoantibodies against contactin ‐associated protein 1 and complexes of paranode‐specific proteins in chronic inflammatory demyelinating polyradiculoneuropathy
ConclusionsThis is the first confirmed Japanese case of anti-Caspr1 antibody-positive CIDP with a clinical signature similar to that of patients of Western origin. Our preliminary study did not identify the presence of specific antibodies against the paranode protein complexes, and the primary target antigen is likely Caspr1. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - November 12, 2022 Category: Neurology Authors: Michiaki Koga,
Toshihiko Maeda,
Fumitaka Shimizu,
Takashi Kanda Tags: ORIGINAL ARTICLE Source Type: research
Autoantibodies against contactin ‐associated protein‐1 and complexes of paranode‐specific proteins in chronic inflammatory demyelinating polyradiculoneuropathy
ConclusionsThis is the first confirmed Japanese case of anti-Caspr1 antibody-positive CIDP with a clinical signature similar to that of patients of western origins. Our preliminary study did not identify the presence of specific antibodies against the paranode protein complexes, and the primary target antigen is likely Caspr1. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - October 27, 2022 Category: Neurology Authors: Michiaki Koga,
Toshihiko Maeda,
Fumitaka Shimizu,
Takashi Kanda Tags: ORIGINAL ARTICLE Source Type: research
Level of CSF CXCL10 is highly elevated and decreased after steroid therapy in patients with autoimmune glial fibrillary acidic protein astrocytopathy
ConclusionCSF CXCL10 levels were particularly high in GFAP-A, and changes in levels after treatment correlated with clinical improvements, suggesting CXCL10 involvement in GFAP-A pathogenesis. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - October 26, 2022 Category: Neurology Authors: Takayuki Kikuchi,
Naoki Takao,
Tomoo Sato,
Isahaya Kenji,
Sakae Hino,
Kaburagi Mayumi,
Tachikawa Keiji,
Ko Riyoko,
Soichiro Shibata,
Kei Kaburagi,
Naoki Iijima,
Heisuke Mizukami,
Kenzo Sakurai,
Junji Yamauchi,
Akio Kimura,
Takayoshi Shimoha Tags: ORIGINAL ARTICLE Source Type: research
A case of natalizumab ‐associated progressive multifocal leukoencephalopathy followed by immune reconstitution inflammatory syndrome with difficulty in the timing of immunotherapy
ConclusionsTreatment sequencing should be executed before the onset of NAT-PML. Changes in CSF cell count and IgG index may be useful for treatment decision; further research is needed. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - October 19, 2022 Category: Neurology Authors: Takamichi Sugimoto,
Shuichiro Neshige,
Shiro Aoki,
Kazuhide Ochi,
Ruoyi Ishikawa,
Megumi Nonaka,
Masahiro Nakamori,
Tomohisa Nezu,
Kazuo Nakamichi,
Yu Yamazaki,
Hirofumi Maruyama Tags: CASE REPORT Source Type: research
The level of CSF CXCL10 is highly elevated and decreased after steroid therapy in patients with autoimmune glial fibrillary acidic protein astrocytopathy
ConclusionsCSF CXCL10 levels were particularly high in GFAP-A, and changes in levels after treatment correlated with clinical improvements, suggesting CXCL10 involvement in GFAP-A pathogenesis. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - October 11, 2022 Category: Neurology Authors: Takayuki Kikuchi,
Naoki Takao,
Tomoo Sato,
Kenji Isahaya,
Sakae Hino,
Kaburagi Mayumi,
Tachikawa Keiji,
Ko Riyoko,
Soichiro Shibata,
Kei Kaburagi,
Naoki Iijima,
Heisuke Mizukami,
Kenzo Sakurai,
Junji Yamauchi,
Akio Kimura,
Takayoshi Shimoha Tags: ORIGINAL ARTICLE Source Type: research
Balo's concentric sclerosis or multiple sclerosis? A demyelinating disease in a 36 ‐year‐old woman
(Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - October 5, 2022 Category: Neurology Authors: Jingya Wei,
Sa Wang,
Juan Kang Tags: CASE IMAGE Source Type: research
Japan MG Registry: chronological surveys over 10 years
AbstractThe primary purpose of the Japanese myasthenia gravis registry (JAMG-R) has been to research and promote high-quality medical care for MG patients in Japan. We reviewed the findings of surveys performed by JAMG-R over an approximately 10-year period. The first goal for favorable quality of life (QOL) is a status of minimal manifestations (MM) or better with an oral prednisolone (PSL) dose of 5 mg/day or less (MM-5 mg). Early and aggressive use of non-oral fast-acting treatment together with low-dose oral PSL (the “EFT strategy”) is recommended to reduce disease severity with minimal oral steroid use so that the...
Source: Clinical and Experimental Neuroimmunology - October 1, 2022 Category: Neurology Authors: Shigeaki Suzuki,
Masayuki Masuda,
Akiyuki Uzawa,
Yuriko Nagane,
Shingo Konno,
Yasushi Suzuki,
Tomoya Kubota,
Takamichi Sugimoto,
Makoto Samukawa,
Genya Watanabe,
Kei Ishizuchi,
Hiroyuki Akamine,
Yosuke Onishi,
Kazuki Yoshizumi,
Takafumi Uchi Tags: INVITED REVIEW Source Type: research
Concentration ‐dependent effects of proinflammatory cytokines on barrier function and tight junction protein expression in brain microvascular endothelial cells and the hypothermic and hyperthermic effects on tight junction protein expression
ConclusionThe hypothermic suppression of TNF- α and IL-17 release may contribute to the maintenance of BBB function by ameliorating the decrease of TJP(s). In contrast, hyperthermia may decrease barrier function through a decrease in JAM-B expression. However, the contribution of changes in the JAM-B expression to the barrier function of BMVEC s remains to be clarified. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - September 28, 2022 Category: Neurology Authors: Tomohiro Matsui,
Yuji Mochiduki,
Yusuke Yoshida,
Takenori Nitta Tags: ORIGINAL ARTICLE Source Type: research
Myelin oligodendrocyte glycoprotein antibody ‐associated disease presenting as recurrent acute disseminated encephalomyelitis: Case report of the youngest Mexican patient in the literature
ConclusionsInformation regarding the clinical presentation and evolution among different population could help to a better understanding of the presentation of this entity. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - September 27, 2022 Category: Neurology Authors: Christian Garc ía‐Estrada,
Enrique Gómez‐Figueroa,
Juan Pablo Morelos‐Cisneros,
Alondra Deras‐Martinez Tags: CASE REPORT Source Type: research
